methyl 3-hydroxy-4-[4-(2-hydroxyethyl)benzyl]benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-hydroxy-4-[4-(2-hydroxyethyl)benzyl]benzoate
• 英文别名: Methyl 3-hydroxy-4-[[4-(2-hydroxyethyl)phenyl]methyl]benzoate
• 化学式: C₁₇H₁₈O₄
• 分子量: 286.328
• InChiKey: BEXCDMXDHWZLRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3-hydroxy-4-[4-(2-hydroxyethyl)benzyl]benzoate 生成 2-[4-(2-acetoxyethyl)benzyl]-5-acetoxymethylphenol
  参考文献：
  名称：

  GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES

  摘要：

  公开号：

  EP1270584B1
• 作为产物：
  描述：

  methyl 3-hydroxy-4-(hydroxy(4-(2-hydroxyethyl)phenyl)methyl)benzoate 在 10% palladium on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 14.0h， 生成 methyl 3-hydroxy-4-[4-(2-hydroxyethyl)benzyl]benzoate
  参考文献：
  名称：

  GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1367060B1

文献信息

• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：Fujikura Hideki

  公开号：US20050080022A1

  公开（公告）日：2005-04-14

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃基氧基苄基苯衍生物：其中R1表示氢原子或羟基（较低烷基）基团；R2表示较低烷基基团、较低烷氧基团、较低烷基硫基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐。该化合物在人类SGLT2中具有优异的抑制活性，可用作预防或治疗糖尿病、肥胖等的药物，以及其中间体。
• Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
  申请人：——

  公开号：US20040138148A1

  公开（公告）日：2004-07-15

  The present invention provides glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein P represents a hydrogen atom or a group forming a prodrug; R 1 represents a hydrogen atom, an optionally substituted amino group, a carbamoyl group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkylthio group, etc., which have an improved oral absorption, and exert an inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, or pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.

  本发明提供了由下式表示的葡萄糖吡喃基氧基苄基苯衍生物：1其中P代表氢原子或形成前药的基团；R1代表氢原子、可选取代氨基、氨基甲酰基、可选取代的低碳基、可选取代的低碳氧基等；R2代表氢原子或低碳基；R3代表可选取代的低碳基、可选取代的低碳氧基、可选取代的低碳硫基等。这些衍生物具有良好的口服吸收性，并在人类SGLT2中表现出抑制活性，因此可用于预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症，或其药学上可接受的盐和药用用途。
• Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
  申请人：——

  公开号：US20040053855A1

  公开（公告）日：2004-03-18

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein R 1 represents a hydrogen atom or a hydroxy(lower alkyl) group; and R 2 represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a hydroxy(lower alkyl) group, a hydroxy(lower alkoxy) group, a hydroxy(lower alkylthio) group etc., and salts thereof, which have an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, obesity etc., and intermediates thereof.

  本发明涉及一种由通式1所表示的葡萄糖吡喃基氧基苯基苯基衍生物，其中R1代表氢原子或羟基（较低烷基）基团；R2代表较低烷基基团、较低烷氧基基团、较低烷基硫基基团、羟基（较低烷基）基团、羟基（较低烷氧基）基团、羟基（较低烷基硫基）基团等，以及其盐，具有出色的人类SGLT2抑制活性，并可用作糖尿病、肥胖等的预防或治疗药物及其中间体。
• US7045665B2
  申请人：——

  公开号：US7045665B2

  公开（公告）日：2006-05-16
• US7465712B2
  申请人：——

  公开号：US7465712B2

  公开（公告）日：2008-12-16